Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

1. Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia

Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Here is some important information for everyone to keep in mind. Featured topics 30 Mar 2020 30 Mar 2020 30 Mar 2020 Featured article Information for consumers about (...) information for Australian health professionals and consumers. Featured resources 19 February 2020 19 February 2020 8 January 2020 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia PBS listings

2020 National Prescribing Service Limited (Australia)

2. Risperidone

Risperidone Top results for risperidone - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for risperidone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. (Abstract)

In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. 28320006 2017 12 08 2018 12 02 1539-3704 166 6 2017 03 21 Annals of internal medicine Ann. Intern. Med. In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo. JC32 10.7326/ACPJC-2017-166-6-032 Lee Justin J Holbrook Anne A McMaster UniversityHamilton, Ontario, Canada. eng Journal Article Comment United States Ann Intern Med 0372351 0003-4819 (...) 0 Antipsychotic Agents J6292F8L3D Haloperidol L6UH7ZF8HC Risperidone AIM IM JAMA Intern Med. 2017 Jan 1;177(1):34-42 27918778 Antipsychotic Agents Delirium Double-Blind Method Haloperidol Humans Palliative Care Risperidone 2017 3 21 6 0 2017 3 21 6 0 2017 12 9 6 0 ppublish 28320006 2612421 10.7326/ACPJC-2017-166-6-032

2017 Annals of Internal Medicine Controlled trial quality: uncertain

4. Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations Full Text available with Trip Pro

Two cases of life‐threatening arrhythmia induced by risperidone: evaluation of risperidone and 9‐hydroxy‐risperidone concentrations Case 1: A 20-year-old woman suffering a suspected overdose was transported to the hospital. She presented bradycardia with wide QRS waves and QT prolongation, followed by cardiac arrest. Extracorporeal cardiopulmonary resuscitation was implemented, improving circulation. Risperidone and 9OH-RIS levels were 9.6 ng/mL and 127.6 ng/mL, respectively. Case 2: A 54 (...) -year-old woman was hospitalized for femoral fracture and underwent surgery. Her electrocardiogram showed bradycardia and complete AV block. Risperidone and 9OH-RIS levels were 3.2 ng/mL and 61.4 ng/mL, respectively.In both cases, only serum concentration of 90H-RIS were elevated.Arrhythmia related to risperidone has proven rare but sometimes fatal. Serum concentrations of risperidone and the metabolite 9-hydroxy-risperidone (9OH-RIS) during these events are seldom documented. As 9OH-RIS shows

2017 Acute medicine & surgery

5. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. (Abstract)

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms.In this randomised, double-blind, phase 3b trial, we enrolled (...) adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day); previous

2017 Lancet Controlled trial quality: predicted high

6. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Full Text available with Trip Pro

Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%.To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children.In a 6-week double (...) -blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners' Parent Rating Scale (CPRS-48), Children's Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher's exact tests in the SPSS 19

2016 Electronic physician Controlled trial quality: uncertain

7. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. Full Text available with Trip Pro

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics.This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone.Thirty patients taking risperidone were enrolled (...) improved erectile dysfunction in five out of six patients. There were no significant differences in change in psychopathology or side-effects between groups.Adjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. This is a potential treatment for hyperprolactinaemia observed during treatment with second-generation antipsychotics.None.© The Royal College of Psychiatrists 2015. This is an open access article

2016 BJPsych open Controlled trial quality: uncertain

8. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Full Text available with Trip Pro

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar

2016 Cochrane

9. Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis

Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis Long-acting injectable risperidone as an option in first-episode psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting injectable risperidone as an option in first-episode psychosis Article Text Electronic pages Pharmacological interventions Long-acting injectable risperidone as an option in first-episode psychosis Nancy H

2016 Evidence-Based Mental Health

10. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Article Text Causes and risk factors Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D 2/3 receptor occupancy following risperidone and olanzapine dose reduction Hiroyoshi Takeuchi , Gary Remington Statistics from Altmetric.com ABSTRACT FROM: Graff-Guerrero A, Rajji TK, Mulsant BH, et al . Evaluation of antipsychotic

2015 Evidence-Based Mental Health

11. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia HAS - Medical, Economic and Public Health Assessment Division 1/16 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated tablet B/60 (CIP (...) for injection in prefilled syringe B/1 (CIP: 34009 362 494 2 4) HAS - Medical, Economic and Public Health Assessment Division 2/16 Applicant: JANSSEN-CILAG INN Risperidone ATC code N05AX08 (Antipsychotics) Reason for the review Renewal of inclusion Extension of indication in the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer's dementia unresponsive to non pharmacological approaches and when there is a risk of harm to self or others. Lists

2014 Haute Autorite de sante

12. Risperidone

Risperidone USE OF RISPERIDONE IN PREGNANCY 0344 892 0909 USE OF RISPERIDONE IN PREGNANCY (Date of issue: January 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Risperidone is an atypical antipsychotic used in the treatment (...) of schizophrenia, mania, and for the short term management of persistent aggression. Although risperidone exposures are included in a number of studies which report on fetal outcome for cohorts of women exposed to various antipsychotics, the percentage and absolute number of risperidone exposures in each of these cohorts is generally very small and no separate analysis for risperidone was undertaken. The very limited data that are available for risperidone specifically do not provide evidence of an increased

2014 UK Teratology Information Service

13. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD

Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) to augmentation with risperidone for treating adults with treatment-resistant OCD Article Text Psychological interventions Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD Joseph O'Neill Statistics from Altmetric.com What is already known on this topic? For adult patients with obsessive-compulsive disorder (OCD) resistant to serotonin reuptake inhibitors (SRIs), American Psychological Association practice

2014 Evidence-Based Mental Health

14. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

15. Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders Full Text available with Trip Pro

Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence that risperidone reduces aggression

2013 Evidence-Based Mental Health

16. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Article Text Therapeutics Long-acting risperidone increases medication

2013 Evidence-Based Mental Health

17. Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery

Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery Cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery have been (...) reported in patients taking the atypical antipsychotics risperidone or paliperidone. Published 11 December 2014 From: Therapeutic area: , , , Article date: November 2013 Intraoperative floppy iris syndrome (IFIS) is a complication observed during cataract surgery that was first described in 2005 in association with the α1-adrenergic antagonist tamsulosin. α1-adrenergic receptors are present in the iris dilator muscle of the eye, where inhibition of the receptors relaxes this muscle causing a floppy

2013 MHRA Drug Safety Update

18. Relapse risk after discontinuation of risperidone in Alzheimer's disease. (Abstract)

Relapse risk after discontinuation of risperidone in Alzheimer's disease.

2012 NEJM

19. Cost-effectiveness analysis of olanzapine and risperidone in Norway

Cost-effectiveness analysis of olanzapine and risperidone in Norway Cost-effectiveness analysis of olanzapine and risperidone in Norway Cost-effectiveness analysis of olanzapine and risperidone in Norway Kim K, Aas E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of two atypical antipsychotics, olanzapine and risperidone, for the treatment of schizophrenia. Due to the uncertainty in the results, the authors could not conclude that olanzapine was more cost-effective than risperidone, in Norway, but they stated that the model could be useful with more reliable trial data. The methods were robust and various areas of uncertainty were considered. The authors’ conclusions appear to be valid. Type

2012 NHS Economic Evaluation Database.

20. Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder

Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder Article Text

2012 Evidence-Based Mental Health